ICON Public (NASDAQ:ICLR) Price Target Raised to $363.00 at Robert W. Baird

ICON Public (NASDAQ:ICLR) had its target price upped by stock analysts at Robert W. Baird from $362.00 to $363.00 in a report issued on Friday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Robert W. Baird’s price objective would indicate a potential upside of 20.97% from the company’s previous close.

A number of other research firms have also recently commented on ICLR. Barclays lifted their target price on ICON Public from $325.00 to $355.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Truist Financial boosted their price target on ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Mizuho restated a “buy” rating and issued a $346.00 price target on shares of ICON Public in a research report on Thursday, April 4th. Finally, Evercore ISI boosted their price target on ICON Public from $325.00 to $350.00 and gave the company an “outperform” rating in a research report on Friday, February 23rd. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $319.55.

ICON Public Stock Down 3.0 %

Shares of NASDAQ ICLR opened at $300.08 on Friday. The company has a market capitalization of $24.76 billion, a price-to-earnings ratio of 36.51, a price-to-earnings-growth ratio of 1.46 and a beta of 1.15. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.21 and a quick ratio of 1.21. The business has a 50-day moving average of $318.31 and a two-hundred day moving average of $282.20. ICON Public has a 1 year low of $181.92 and a 1 year high of $344.77.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 21st. The medical research company reported $3.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.27 by $0.13. The company had revenue of $2.07 billion during the quarter, compared to the consensus estimate of $2.08 billion. ICON Public had a return on equity of 11.84% and a net margin of 8.30%. On average, analysts forecast that ICON Public will post 14.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Institutional investors and hedge funds have recently bought and sold shares of the stock. Liontrust Investment Partners LLP lifted its stake in ICON Public by 108.4% in the 3rd quarter. Liontrust Investment Partners LLP now owns 89,860 shares of the medical research company’s stock valued at $22,129,000 after buying an additional 46,739 shares in the last quarter. Chartwell Investment Partners LLC increased its holdings in shares of ICON Public by 16.1% during the 3rd quarter. Chartwell Investment Partners LLC now owns 6,953 shares of the medical research company’s stock worth $1,712,000 after buying an additional 963 shares during the last quarter. Whittier Trust Co. increased its holdings in shares of ICON Public by 6.2% during the 4th quarter. Whittier Trust Co. now owns 2,702 shares of the medical research company’s stock worth $765,000 after buying an additional 158 shares during the last quarter. Cullen Investment Group LTD. acquired a new stake in shares of ICON Public during the 4th quarter worth $1,620,000. Finally, Prime Capital Investment Advisors LLC acquired a new stake in shares of ICON Public during the 4th quarter worth $416,000. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.